Paul Wotton - Cynata Therapeutics Director
| CYYNF Stock | USD 0.11 0.00 0.00% |
Director
Dr. Paul Kevin Wotton is the Chairman of the Board of the Company. Dr Wotton has more than 30 years experience in the pharmaceuticals and biotech industry. He is currently the President and CEO of Sigilon Inc, having previously served as President and CEO of Ocata Therapeutics from July 2014 until it was acquired by Astellas for US379 million in February of 2016. Prior to that he served for 6 years as CEO and President of Antares Pharma, Inc., a Nasdaqlisted specialty pharmaceutical company. Before leading Antares Pharma he held various senior executive roles in large and midcap pharma and biotech companies in the USA and Europe. He is a member of the boards of Vericel Corporationrationration, a US company developing autologous cellular therapies and Veloxis Pharmaceuticals AS. Dr Wotton is a pharmacist by training with both a Ph.D. from the University of Nottingham and an MBA from Kingston Business School in the U.K. In 2014 he was named New Jersey EY Entrepreneur of the Year in Life Sciences. since 2017.
| Age | 57 |
| Tenure | 7 years |
| Professional Marks | MBA |
| Phone | 61 3 7067 6940 |
| Web | https://www.cynata.com |
Paul Wotton Latest Insider Activity
Tracking and analyzing the buying and selling activities of Paul Wotton against Cynata Therapeutics pink sheet is an integral part of due diligence when investing in Cynata Therapeutics. Paul Wotton insider activity provides valuable insight into whether Cynata Therapeutics is net buyers or sellers over its current business cycle. Note, Cynata Therapeutics insiders must abide by specific rules, including filing SEC forms every time they buy or sell Cynata Therapeutics'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Paul Wotton over three months ago Sale by Paul Wotton of 5000 shares of Vericel Corp | ||
Paul Wotton over six months ago Acquisition by Paul Wotton of 6500 shares of Vericel Corp subject to Rule 16b-3 | ||
Paul Wotton over six months ago Exercise or conversion by Paul Wotton of 2600 shares of Vericel Corp subject to Rule 16b-3 |
Cynata Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.1342) % which means that it has lost $0.1342 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.2081) %, meaning that it generated substantial loss on money invested by shareholders. Cynata Therapeutics' management efficiency ratios could be used to measure how well Cynata Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| William Li | Ceapro Inc | 49 | |
| Myrna Francis | Covalon Technologies | N/A | |
| Joseph Cordiano | Covalon Technologies | N/A | |
| Jeffrey Mandel | Covalon Technologies | N/A | |
| John Hands | Covalon Technologies | N/A | |
| Murray Miller | Covalon Technologies | N/A | |
| John Zupancic | Ceapro Inc | N/A | |
| Elinor Caplan | Covalon Technologies | N/A | |
| Ian Brindle | Covalon Technologies | N/A | |
| Martin Bernholtz | Covalon Technologies | N/A | |
| Ulrich Kosciessa | Ceapro Inc | N/A | |
| Glenn Rourke | Ceapro Inc | N/A | |
| Gale Pollock | Covalon Technologies | N/A | |
| Ronald Smith | Covalon Technologies | 66 | |
| John Suk | Covalon Technologies | N/A | |
| Donald Oborowsky | Ceapro Inc | N/A | |
Management Performance
| Return On Equity | -0.21 | |||
| Return On Asset | -0.13 |
Cynata Therapeutics Leadership Team
Elected by the shareholders, the Cynata Therapeutics' board of directors comprises two types of representatives: Cynata Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Cynata. The board's role is to monitor Cynata Therapeutics' management team and ensure that shareholders' interests are well served. Cynata Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Cynata Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Stewart Washer, Executive Chairman of the Board | ||
| Geoffrey Brooke, Independent Non-Executive Director | ||
| Ross Macdonald, CEO, Managing Director, Executive Director | ||
| BBus FCIS, Company Sec | ||
| Kilian Kelly, VP of Product Devel. | ||
| Peter Webse, Company Secretary, Non-Executive Director | ||
| John Chiplin, Non-Executive Independent Director | ||
| Suzanne Lipe, Vice President - Alliance Management | ||
| Jolanta Airey, Chief Officer | ||
| Paul Wotton, Director |
Cynata Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Cynata Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.21 | |||
| Return On Asset | -0.13 | |||
| Profit Margin | (0.70) % | |||
| Operating Margin | (0.78) % | |||
| Current Valuation | 12.47 M | |||
| Shares Outstanding | 143.28 M | |||
| Shares Owned By Insiders | 14.77 % | |||
| Shares Owned By Institutions | 24.80 % | |||
| Price To Book | 2.66 X | |||
| Price To Sales | 5.53 X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Cynata Therapeutics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Cynata Therapeutics' short interest history, or implied volatility extrapolated from Cynata Therapeutics options trading.
Pair Trading with Cynata Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Cynata Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Cynata Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving against Cynata Pink Sheet
| 0.68 | VRTX | Vertex Pharmaceuticals Financial Report 6th of May 2024 | PairCorr |
| 0.63 | REGN | Regeneron Pharmaceuticals Financial Report 2nd of May 2024 | PairCorr |
| 0.47 | WXIBF | WuXi Biologics | PairCorr |
The ability to find closely correlated positions to Cynata Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Cynata Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Cynata Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Cynata Therapeutics Limited to buy it.
The correlation of Cynata Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Cynata Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Cynata Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Cynata Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cynata Therapeutics Limited. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. You can also try the Equity Valuation module to check real value of public entities based on technical and fundamental data.
Complementary Tools for Cynata Pink Sheet analysis
When running Cynata Therapeutics' price analysis, check to measure Cynata Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cynata Therapeutics is operating at the current time. Most of Cynata Therapeutics' value examination focuses on studying past and present price action to predict the probability of Cynata Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cynata Therapeutics' price. Additionally, you may evaluate how the addition of Cynata Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Stocks Directory Find actively traded stocks across global markets | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities |